Development of a ncRNA DNA Methylation Kit for the Diagnosis of Cancer of Unknow...
Development of a ncRNA DNA Methylation Kit for the Diagnosis of Cancer of Unknown Primary
The innovative idea behind the EPICUP (EPIgenetics of Cancer of Unknown Primary) project is to develop a package demonstrating the feasibility of a high-throughput tool for epigenotyping Cancer of Unknown Primary (CUP) to identify...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
EPIPHARM
Development of a ncRNA DNA Methylation Kit for Treatment Gui...
149K€
Cerrado
COMBICODE
Decoding the Combinatorial Epigenetic Information of the Mam...
Cerrado
EPIDIACAN
Development of sensitive methodologies for exploitation of e...
4M€
Cerrado
SAF2009-08663
CARACTERIZACION EPIGENOMICA DE LAS NEOPLASIAS HEMATOLOGICAS
114K€
Cerrado
OR-HMC
Assay for cancer diagnostics by quantification of 5hmC
150K€
Cerrado
EpiCblood
Towards early cancer detection and tumor classification usin...
1M€
Cerrado
Información proyecto EPICUP
Duración del proyecto: 11 meses
Fecha Inicio: 2015-02-02
Fecha Fin: 2016-01-31
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The innovative idea behind the EPICUP (EPIgenetics of Cancer of Unknown Primary) project is to develop a package demonstrating the feasibility of a high-throughput tool for epigenotyping Cancer of Unknown Primary (CUP) to identify tumor type based in the DNA methylation profile of non-coding RNA (ncRNA) loci. CUPs are a heterogeneous group of cancers defined by the presence of metastatic disease with no identified primary tumor at presentation. In those CUPs where the primary tumor type is not identified, the outcome is extremely poor with an expected death within the first six months of the diagnosis. CUP has been reported to comprise approximately 5% of all cancer cases in the world. Despite the introduction of new image technologies and immunohistochemistry methods, more than 50% of CUPs remain anonymous regarding their primary tumor site of origin and, as mentioned, their prognoses are dismal. As part of the ERC Advanced Grant Epigenetic Disruption on Non-Coding RNAs in Human Cancer (EPINORC), aimed at determining the contribution of DNA methylation alterations to the aberrant activity of ncRNA loci in human cancer, we have used the most advanced DNA methylation microarray technology to detect CpG methylation changes in a wide variety of ncRNAs (microRNAs, lincRNAs, T-UCRs, snoRNAs, piRNAs...) that show a tumor-type specific pattern. In the current EPICUP Proof of Concept (PoC) proposal, we plan to optimize a ncRNA DNA methylation assay that includes a user-friendly and cost effective approach to improve the clinical diagnosis of CUP cases to an extent that will make it interesting commercially for the health providers and their associated company partners.